Iovance Biotherapeutics, Inc. - Common Stock – Cashflow (NASDAQ:IOVA)

Financials

Mittelzufluss aus laufender Geschäftstätigkeit -205.13 M-227.94 M-292.76 M-361.82 M-352.98 M-302.41 M -270.79 M Mittelzufluss aus Investitionstätigkeit -317.85 M132 K256.45 M-155.24 M-96.41 M47.5 M 43.02 M Zahlungsströme aus der Finanzierungstätigkeit 576.42 M239.27 M190.15 M462.96 M390.66 M300.77 M 251.79 M Freier Cashflow -205.13 M-227.94 M-292.76 M-361.82 M-352.98 M-336.24 M -305.02 M

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte therapies against cancer.

IOVA

Financials

Iovance Biotherapeutics, Inc. - Common Stock

Nachrichten

IBRX Stock Outlook After Q1 Results and a New FDA Review

ImmunityBio: Anktiva Explained and What Comes Next

AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates

Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates

Undercovered Stocks: Western Digital, SAP, Toast And More

Pacira (PCRX) Q1 Earnings Miss Estimates

Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Regeneron (REGN) Surpasses Q1 Earnings and Revenue Estimates

Iovanace Biotherapeutics: H.C. Wainwright bekräftigt "Buy"-Rating und Kursziel